Retinal Artery Occlusion
Retinal artery occlusion refers to blockage of the retinal artery carrying oxygen to the nerve cells in the retina at the back of the eye. The lack of oxygen delivery to the retina may result in severe loss of vision.
Retinal artery occlusion is usually associated with sudden painless loss of vision in one eye. The area of the retina affected by the blocked vessels determines the area and extent of visual loss.
- The main artery supplying blood to the eye is the ophthalmic artery; when it is blocked, it produces the most damage. A blockage in the main artery in the retina is called central retinal artery occlusion (CRAO), which often results in severe loss of vision. However, about 25% of people who develop CRAO have an extra artery called a cilioretinal artery in their eyes. When CRAO occurs, having a cilioretinal artery can greatly lessen the chances of damage to your central vision, as long as the cilioretinal artery is not affected.
- A blockage in a smaller artery is called branch retinal artery occlusion (BRAO); this may cause a loss of a section of your visual field, such as your vision to one side. If the affected area is not in the center of the eye or is relatively small, a BRAO may go unnoticed with no symptoms.
Retinal artery occlusion occurs due to blockage of the retinal artery, often by an embolus (a small piece of cholesterol that blocks blood flow) or thrombus (blood clot). The retinal artery occlusion may be transient and last for only a few seconds or minutes if the blockage breaks up and restores
blood flow to the retina, or it may be permanent.
Common risk factors include:
- Carotid artery disease
- Atherosclerosis (fatty deposits in the arteries)
- Faulty heart valves (valvular heart disease)
- Tumors in the heart (myxoma)
- Abnormal heart rhythms such as atrial fibrillation
- High blood pressure
- Intravenous drug abuse
- Giant-cell arteritis
- Disorders contributing to blood clot formation, such as sickle cell disease
- Use of oral contraceptives
- Homocystinuria (a hereditary disorder that prevents your body from processing the amino acid methionine; this leads to an excess accumulation of homocysteine in the blood and urine)
- Blood platelet abnormalities
Most retinal artery occlusion patients are in their 60s, and are more commonly men than women. Only 1% to 2% of cases involve both eyes.
CRAO is usually diagnosed by a dilated eye examination that shows a “cherry red spot,” where the center of the macula appears red, with the surrounding retina pale due to the lack of blood flow. (Figure 1) BRAO appears as an area of superficial retinal whitening along the blocked vessel.(Figure 2)
The whitening of the retina generally lasts 4 to 6 weeks before fading. Fluorescein angiography (FA) shows a delay in filling of the retinal arteries. (Figure 3) Optical coherence tomography (OCT) provides detailed images of the central retina, and shows swelling in the inner layers of the retina in the affected area, which over time atrophy, becoming much thinner than normal.
Figure 1. Central retinal vein occlusion (CRAO) with cherry red spot. Mehul A. Shah, MD. Retina Image Bank 2014; Image 19815. ©American Society of Retina Specialists.
Figure 2. Branch retinal vein occlusion (BRAO) showing retinal whitening in the area of blockage. John S. King, MD. Retina Image Bank 2014; Image 18552. ©American Society of Retina Specialists.
Figure 3. Fluorescein angiogram of CRAO showing sparing of the cilioretinal artery. Courtney Crawford, MD. Retina Image Bank 2017; Image 26792. ©American Society of Retina Specialists.
Treatment and prognosis
Unfortunately, there is no clinically proven treatment for CRAO. Several therapies may be used including:
- Hyperventilation—inhaling carbogen, a mixture of 95% oxygen and 5% carbon dioxide, to attempt to dilate the retinal arteries and cause the clot to dislodge
- Paracentesis (removal of fluid from the front of the eye using a small-gauge needle) to lower
- the intraocular pressure to try to dislodge the embolus
- Lowering the intraocular pressure with medication
- Ocular massage with a thumb to dislodge the clot
However, for any treatment to be potentially effective in CRAO, it must be deployed within a short time window, probably within 4 to 6 hours after symptoms begin. Unfortunately, none of these therapies have been shown to predictably alter the natural history of disease.
Thrombolytic therapy (“clot-busting” drugs), delivered either intravenously or directly through the ophthalmic artery, has also been tried but clinical trials have not shown this treatment to be effective.
An important aspect of managing retinal artery occlusion is for your doctor to identify and manage risk factors that may lead to other vascular conditions. The risk factors for CRAO are the same atherosclerotic risk factors as for stroke and heart disease; tests are important to try to identify the source of a clot from another part of the body. These tests include:
- A carotid ultrasound to determine whether there are carotid plaques present
- Cardiac echocardiography to look for disease in the heart valves
A doctor may also order a test of your blood’s sedimentation rate, and a temporal artery biopsy may be useful if giant cell arteritis is suspected.
Vision loss with CRAO is usually severe. However, CRAOs in patients who have a cilioretinal artery have better visual prognosis, usually recovering to 20/50 vision or better in over 80% of eyes. Visual field loss in BRAO is usually permanent, but central visual acuity may recover to 20/40 or better in 80% of eyes.
Formation of new blood vessels of the retina or iris that are prone to bleed is a rare complication seen after a CRAO or BRAO. Growth of these vessels can further decrease vision by causing vitreous hemorrhage and glaucoma. If this happens, laser photocoagulation therapy is used to create burns in the area of the blocked artery to try to lower the oxygen demand of the retina and thus stop the abnormal blood vessels from growing.
Intravitreal injections of anti-VEGF medications such as Avastin® (bevacizumab), Lucentis® (ranibizumab) or Eylea® (aflibercept) may also be used in such cases.